{
    "title": "108_hr2356",
    "content": "The Act titled \"Prescription Drug Comparative Effectiveness Act of 2003\" requires NIH research and AHRQ study on the effectiveness of certain prescription drugs. The Prescription Drug Comparative Effectiveness Act of 2003 mandates NIH research and AHRQ analysis to develop scientific evidence on the comparative effectiveness, cost-effectiveness, and safety of prescription drugs compared to other treatments for the same disease or condition. The Prescription Drug Comparative Effectiveness Act of 2003 requires practice centers to analyze the comparative effectiveness, cost-effectiveness, and safety of prescription drugs in comparison to other treatments for the same disease. The Director of the Agency for Healthcare Research and Quality will develop standards in consultation with other relevant stakeholders. The Director of the Agency for Healthcare Research and Quality, in consultation with stakeholders, will establish standards for cost-effectiveness studies on covered prescription drugs. These drugs are determined by the Director of the Agency for Healthcare Research and Quality to have high expenditures in federally funded health programs. Additionally, an annual report on research results will be submitted to Congress. The Director of the Agency for Healthcare Research and Quality will prepare and submit reports to various entities including Congress, the Secretary of Defense, and the Secretary of Health and Human Services. Additionally, reports for practitioners will be transmitted to the Director of the National Institutes of Health after completion of any study. The Director of the National Institutes of Health will publish reports on their website and other accessible platforms for practitioners. Only methodologically sound studies will be considered, with a preference for those with sufficient data and analysis. Appropriations are authorized for the National Institutes of Health to carry out this section. The National Institutes of Health is authorized $50,000,000 for fiscal year 2004 and subsequent years, while the Agency for Healthcare Research and Quality is authorized $25,000,000 for fiscal year 2004 and subsequent years to carry out this section."
}